Comments
The US Food & Drug Administration (USFDA) has completed a GMP inspection at Dr Reddy’s Laboratories’ API manufacturing facility (CTO-3) in Bollaram, Hyderabad.
The inspection was conducted from June 12, 2023, to June 16, 2023. The inspection closed with zero observations.
The formulations manufacturing facility in Srikakulam (FTO SEZ PU2) of the Hyderabad-based Dr Reddy’s has also received the Establishment Inspection Report (EIR) from the USFDA.
The Agency has classified the inspection as Voluntary Action Indicated (VAI) and concluded that the inspection is “closed”, the company said.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.